- This is the first in a series on blog posts providing notes and analysis from the earnings conference calls of the "Big Pharma" (term defined very loosely) partners of the stocks I cover here at BiotechDueDiligence.
- Cubist is partnered with Alnylam for an RNAI program against Respiratory Syncytial Civrus (RSV) - get full details at the ALNY research page.
- Cubist is co-promoting the antibiotic Dificid (fidaxomycin) with Optimer Pharma - get full details on the OPTR research page.
- Click here to access the CBST conference call transcript via Morningstar.
- See below the jump for excerpts and notes:
Your support is greatly appreciated